Literature DB >> 26134505

Hyper-osmolarity and calcium chelation: Effects on cystic fibrosis mucus.

Anna Ermund1, Lauren N Meiss2, Jenny K Gustafsson3, Gunnar C Hansson4.   

Abstract

A non-functional Cystic Fibrosis Transmembrane conductance Regulator (CFTR) leads to the disease cystic fibrosis (CF). Although the CFTR is expressed in multiple organs, pulmonary disease is the major cause of illness and death in patients with CF. Stagnant mucus, causing airway obstruction, bacterial overgrowth, persistent inflammation and tissue destruction characterizes the disease, but how the defect in CFTR function is coupled to the mucus phenotype is still controversial. We have recently shown that bicarbonate ions passing through CFTR are necessary for proper unfolding of the MUC2 mucin, thus highlighting the importance of bicarbonate ion transport via the CFTR and the ability of these ions to raise the pH and chelate calcium bound to the mucin as the important steps in forming normal mucus. In order to find potential CF treatments and expand our knowledge about the usefulness of bicarbonate as an active ingredient in formulations to alleviate mucus plugging, we used an Ussing-type chamber and explants from the F508del-CFTR mutant mouse ileum to test the effect of calcium chelators on mucus attachment, either in isolation or in combination with osmolytes such as mannitol or hypertonic saline. We found that increasing the concentration of bicarbonate, both alone or in combination with increased osmolarity of the solution, detached the otherwise attached CF mucus.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  2,2ʹ,2ʺ,2‴-(Ethane-1,2-diyldinitrilo)tetraacetic acid (PubChem CID: 6049); Calcium chelator; Carbachol (2-carbamoyloxyethyl(trimethyl)azanium; Erdosteine (PubChem CID: 65632); Hyperosmolarity; Mouse ileum; Mucus attachment; N-acetyl-l-cysteine (PubChem CID: 12035); Osmolyte; Prostaglandin E(2) (PubChem CID: 5280360); Sodium bicarbonate (PubChem CID: 767); chloride) (PubChem CID: 5831); d-mannitol (PubChem CID:6251)

Mesh:

Substances:

Year:  2015        PMID: 26134505      PMCID: PMC4600443          DOI: 10.1016/j.ejphar.2015.06.051

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  34 in total

1.  Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study.

Authors:  Moira L Aitken; Gabriel Bellon; Kris De Boeck; Patrick A Flume; Howard G Fox; David E Geller; Eric G Haarman; Helge U Hebestreit; Allen Lapey; I Manjula Schou; Jonathan B Zuckerman; Brett Charlton
Journal:  Am J Respir Crit Care Med       Date:  2011-12-28       Impact factor: 21.405

2.  Cystic fibrosis.

Authors:  Steven M Rowe; Stacey Miller; Eric J Sorscher
Journal:  N Engl J Med       Date:  2005-05-12       Impact factor: 91.245

Review 3.  Therapeutic options for hydrating airway mucus in cystic fibrosis.

Authors:  Bernadett E Tildy; Duncan F Rogers
Journal:  Pharmacology       Date:  2015-03-19       Impact factor: 2.547

Review 4.  Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis.

Authors:  Julian Tam; Edward F Nash; Felix Ratjen; Elizabeth Tullis; Anne Stephenson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-12

Review 5.  Mannitol dry powder for inhalation: in patients with cystic fibrosis.

Authors:  Celeste B Burness; Gillian M Keating
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

Review 6.  Airway inflammation in cystic fibrosis: molecular mechanisms and clinical implications.

Authors:  Malena Cohen-Cymberknoh; Eitan Kerem; Thomas Ferkol; Arnon Elizur
Journal:  Thorax       Date:  2013-05-23       Impact factor: 9.139

7.  Dysmotility and proton pump inhibitor use are independent risk factors for small intestinal bacterial and/or fungal overgrowth.

Authors:  C Jacobs; E Coss Adame; A Attaluri; J Valestin; S S C Rao
Journal:  Aliment Pharmacol Ther       Date:  2013-04-10       Impact factor: 8.171

8.  Normal mouse intestinal mucus release requires cystic fibrosis transmembrane regulator-dependent bicarbonate secretion.

Authors:  Mary Abigail S Garcia; Ning Yang; Paul M Quinton
Journal:  J Clin Invest       Date:  2009-08-24       Impact factor: 14.808

9.  A mouse model for the cystic fibrosis delta F508 mutation.

Authors:  J H van Doorninck; P J French; E Verbeek; R H Peters; H Morreau; J Bijman; B J Scholte
Journal:  EMBO J       Date:  1995-09-15       Impact factor: 11.598

Review 10.  State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection?

Authors:  James F Chmiel; Pamela B Davis
Journal:  Respir Res       Date:  2003-08-27
View more
  4 in total

1.  Development of an airway mucus defect in the cystic fibrosis rat.

Authors:  Susan E Birket; Joy M Davis; Courtney M Fernandez; Katherine L Tuggle; Ashley M Oden; Kengyeh K Chu; Guillermo J Tearney; Michelle V Fanucchi; Eric J Sorscher; Steven M Rowe
Journal:  JCI Insight       Date:  2018-01-11

2.  A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.

Authors:  Courtney M Fernandez-Petty; Gareth W Hughes; Hannah L Bowers; John D Watson; Bradley H Rosen; Stacy M Townsend; Carlo Santos; Caroline E Ridley; Kengyeh K Chu; Susan E. Birket; Yao Li; Hui Min Leung; Marina Mazur; Bryan A Garcia; T Idil Apak Evans; Emily Falk Libby; Heather Hathorne; Justin Hanes; Guillermo J Tearney; John P Clancy; John F Engelhardt; William E Swords; David J Thornton; William P Wiesmann; Shenda M Baker; Steven M Rowe
Journal:  JCI Insight       Date:  2019-04-18

Review 3.  Mucus, mucins, and cystic fibrosis.

Authors:  Cameron Bradley Morrison; Matthew Raymond Markovetz; Camille Ehre
Journal:  Pediatr Pulmonol       Date:  2019-11

4.  New generation ENaC inhibitors detach cystic fibrosis airway mucus bundles via sodium/hydrogen exchanger inhibition.

Authors:  Melania Giorgetti; Nikolai Klymiuk; Andrea Bähr; Martin Hemmerling; Lisa Jinton; Robert Tarran; Anna Malmgren; Annika Åstrand; Gunnar C Hansson; Anna Ermund
Journal:  Eur J Pharmacol       Date:  2021-05-08       Impact factor: 4.432

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.